- Home
- SBS vs UTHR Comparison
SBS vs UTHR Comparison
Compare SBS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBS
- UTHR
- Stock Information
- Founded
- SBS 1954
- UTHR 1996
- Country
- SBS Brazil
- UTHR United States
- Employees
- SBS N/A
- UTHR N/A
- Industry
- SBS Water Supply
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- SBS Utilities
- UTHR Health Care
- Exchange
- SBS Nasdaq
- UTHR Nasdaq
- Market Cap
- SBS 14.4B
- UTHR 20.7B
- IPO Year
- SBS 2002
- UTHR 1999
- Fundamental
- Price
- SBS $25.66
- UTHR $446.81
- Analyst Decision
- SBS
- UTHR Buy
- Analyst Count
- SBS 0
- UTHR 12
- Target Price
- SBS N/A
- UTHR $495.08
- AVG Volume (30 Days)
- SBS 834.8K
- UTHR 591.7K
- Earning Date
- SBS 11-10-2025
- UTHR 10-29-2025
- Dividend Yield
- SBS 2.13%
- UTHR N/A
- EPS Growth
- SBS 174.82
- UTHR 16.08
- EPS
- SBS 3.00
- UTHR 26.38
- Revenue
- SBS $7,382,628,649.00
- UTHR $3,128,400,000.00
- Revenue This Year
- SBS N/A
- UTHR $13.68
- Revenue Next Year
- SBS $11.93
- UTHR $5.63
- P/E Ratio
- SBS $8.53
- UTHR $17.03
- Revenue Growth
- SBS 48.83
- UTHR 13.50
- 52 Week Low
- SBS $13.87
- UTHR $266.98
- 52 Week High
- SBS $25.88
- UTHR $479.50
- Technical
- Relative Strength Index (RSI)
- SBS 70.38
- UTHR 56.88
- Support Level
- SBS $24.28
- UTHR $430.02
- Resistance Level
- SBS $25.88
- UTHR $456.41
- Average True Range (ATR)
- SBS 0.38
- UTHR 14.19
- MACD
- SBS 0.12
- UTHR 0.19
- Stochastic Oscillator
- SBS 88.15
- UTHR 51.88
About SBS Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp (Each repstg 250)
Companhia De Saneamento Basico Do Estado De Sao Paulo is engaged in the provision of basic and environmental sanitation services in the Sao Paulo State and supplies treated water and sewage services on a wholesale basis. The company operates in a single segment, which is Sanitation services.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.